[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-384483-105":59,"doc-detail-384483-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","neoadjuvant-immunotherapy-versus-chemoimmunotherapy-in-non-small-cell-lung-cancer-a-protocol-for-systematic-review-and-meta-analysis","Neoadjuvant immunotherapy versus chemoimmunotherapy in non-small cell lung cancer - A protocol for systematic review and meta-analysis","","Lung cancer is a leading cause of cancer morbidity and mortality worldwide, with non-small cell lung cancer (NSCLC) representing roughly 80–85% of cases. Although studies have begun evaluating neoadjuvant immunotherapy or chemoimmunotherapy, no meta-analysis has yet directly compared these approaches in NSCLC. This protocol aims to conduct a systematic review and meta-analysis assessing efficacy and safety, using PRISMA-P guidance and risk-of-bias evaluation for included randomized controlled trials.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/neoadjuvant-immunotherapy-versus-chemoimmunotherapy-in-non-small-cell-lung-cancer-a-protocol-for-systematic-review-and-meta-analysis/384483/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/neoadjuvant-immunotherapy-versus-chemoimmunotherapy-in-non-small-cell-lung-cancer-a-protocol-for-systematic-review-and-meta-analysis/384483.png","ImageObject",300,407,{"name":92,"@type":93},"MrHarris58","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the document trying to compare in NSCLC?","Question",{"text":112,"@type":113},"It compares the efficacy and safety of neoadjuvant immunotherapy versus neoadjuvant chemoimmunotherapy in non-small cell lung cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which types of studies will be included?",{"text":117,"@type":113},"Original clinical randomized controlled trials that assess benefits and safety of neoadjuvant immunotherapy and chemoimmunotherapy in NSCLC will be included.",{"name":119,"@type":110,"acceptedAnswer":120},"How will risk of bias be assessed?",{"text":121,"@type":113},"The protocol uses the Cochrane Collaboration’s tool to assess the risk of bias in the included randomized controlled trials.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},384483,1790837621,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":81,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":39},687212988360,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","®  \nStudy Protocol Systematic Review   \nNeoadjuvant immunotherapy versus chemoimmunotherapy in non-small cell lung cancer  \nA protocol for systematic review and meta-analysis  \nQunying Zhu, MBa , Guini Chen, MBa , Yunzhong Liu, MMa , Yu Zhou, MBb,*   \n\n| Abstract\u003Cbr>Background: Worldwide, lung cancer is the most common cause of cancer morbidity and mortality. Non-small cell lung cancer (NSCLC) accounts for approximately 80 to 85% of all lung cancers. Recently, a few studies have reported the use of neoadjuvant immunotherapy or chemoimmunotherapy in NSCLC. However, no meta-analysis comparing neoadjuvant immunotherapy with chemoimmunotherapy has yet been reported. We perform a protocol for systematic review and meta-analysis to compare the efficacy and safety of neoadjuvant immunotherapy and chemoimmunotherapy in NSCLC.\u003Cbr>Methods: The statement of preferred reporting items for systematic review and meta-analysis protocols will be used as guidelines for reporting the present review protocol. Original clinical randomized controlled trials assessing the beneficial effects and safety of neoadjuvant immunotherapy and chemoimmunotherapy in NSCLC will be included. Databases searched include China National Knowledge Infrastructure, Chinese Scientific Journals Database, Wanfang Database, China Biological Medicine Database, PubMed, EMBASE Database, and Cochrane Central Register of Controlled Trials. Cochrane Collaboration’s tool is used to assess the risk of bias in included randomized controlled trials. All calculations are carried out with Stata 11.0 (The Cochrane Collaboration, Oxford, UK) .\u003Cbr>Results: The results of this systematic review and meta-analysis will be publicly available and published in a peer-reviewed journal.\u003Cbr>Conclusion: This evidence will be useful to practitioners, patients, and health policy-makers regarding the use of neoadjuvant chemoimmunotherapy in NSCLC.\u003Cbr>Abbreviations: NSCLC = non-small cell lung cancer, RCTs = randomized controlled trials, RoB = risk of bias. |\n| --- |\n| Keywords: chemoimmunotherapy, meta-analysis, neoadjuvant immunotherapy, non-small cell lung cancer |\n\n1. Introduction  \nWorldwide, lung cancer is the most common cause of cancer morbidity and mortality. Approximately 247,270 new cases of lung cancer are estimated to occur in 2020, with 130,340 male cases and 116,930 female cases.[1] Prior studies have reported that lung cancer resulted in more deaths than breast cancer, prostate cancer, colorectal cancer, and leukemia combined in men ≥ 40 years old and women ≥ 60 years old. With the introduction of screening guidelines and decrease in tobacco use, the mortality rate for lung cancer has recently decreased by 48% in males and 23% in females. Despite this decrease in mortality rate, approximately 140,730 deaths are estimated to be secondary to lung cancer in 2020.  \nThe greatest risk factor for the development of lung cancer is tobacco use. Secondhand smoking has also been shown to  \nincrease the risk of lung cancer by as much as 26% . Other risk factors for lung cancer include asbestos exposure, family history of lung cancer, and exposure to toxic substances including poly  \ncyclic aromatic hydrocarbons, heavy metals, and radon gas.[2]  \nNon-small cell lung cancer (NSCLC) accounts for approximately 80 to 85% of all lung cancers[3–6]; its treatment depends on tumor histology, genetic subtype, performance status of the patient, and disease stage. Until now, surgery has been the cornerstone; nevertheless, around 40% of completely resected patients develop disease recurrence.[7,8] There is growing enthusiasm for neoadjuvant immunotherapy in patients with resectable NSCLC.[9,10] The proposed benefits of immunotherapy prescribed in the neoadjuvant setting include the increased release of neoantigens from the tumor to stimulate the expansion of specific T-cells, enhanced control of micro-metastases,  \nQZ and GC contributed equally to this work.  \nHainan Provincial Science and Technology Bureau (","cbCaiuxzKXm0Zaum","https://ap.wps.com/l/cbCaiuxzKXm0Zaum","pdf",426564,"English","# Abstract\n# Introduction\n# Methods","[{\"question\":\"What is the document trying to compare in NSCLC?\",\"answer\":\"It compares the efficacy and safety of neoadjuvant immunotherapy versus neoadjuvant chemoimmunotherapy in non-small cell lung cancer.\"},{\"question\":\"Which types of studies will be included?\",\"answer\":\"Original clinical randomized controlled trials that assess benefits and safety of neoadjuvant immunotherapy and chemoimmunotherapy in NSCLC will be included.\"},{\"question\":\"How will risk of bias be assessed?\",\"answer\":\"The protocol uses the Cochrane Collaboration’s tool to assess the risk of bias in the included randomized controlled trials.\"}]","Neoadjuvant immunotherapy versus chemoimmunotherapy in non-small cell lung cancer - A protocol for systematic review and meta-analysis | PDF",1790263620]